In laboratories at the National University of Singapore, researchers have looked to the quiet chemistry of spinach leaves to find a new answer to a condition that quietly diminishes the lives of millions. Dry eye disease, long understood as a cycle of inflammation feeding on itself, may now be interrupted not by suppressing the body's responses but by gifting corneal cells a plant-derived capacity to generate their own protection from light. Published in Cell, the work asks whether one of nature's oldest energy solutions might become medicine's newest tool.
Singapore researchers harness photosynthesis to treat dry eye disease
They gave corneal cells a second way to generate the protective molecule they desperately need
Mark
So they're putting plant cells into the eye? How does that actually work?
Mimi
Not plant cells exactly—they're extracting the photosynthetic machinery from spinach, the structures that plants use to convert light into chemical energy. Then they deliver those structures via eye drops so they can integrate into the corneal cells that are already there.
Luke
Wait, how do they get plant machinery to stay in human cells and actually function? That seems like a huge biological compatibility problem.
Mimi
That's the innovation, right? They've engineered it so the plant-derived photosynthetic components can work inside human corneal cells. The cells harvest ambient light and produce NADPH, which is the antioxidant molecule the eye desperately needs when inflammation is happening.
Mark
And this breaks the cycle they described—the death spiral?
Mimi
Exactly. Inflammation creates reactive oxygen species, which overwhelm the eye's natural defenses, which creates more inflammation. By giving the cells an independent way to produce NADPH, you're essentially giving them a second line of defense that doesn't depend on the eye's damaged systems.
Luke
But this is published research, not a clinical treatment yet. Do we know if it actually works in human eyes, or just in lab conditions?
Mimi
The paper is in Cell, which is a top-tier journal, so the science passed peer review. But you're right—this is still experimental. They've demonstrated the concept works, but human trials would be the next step.
Mark
How soon could patients actually get this?
Luke
That's unknown. Drug development timelines are long, and eye drops that deliver functional biological machinery are not a standard pharmaceutical product. There would be regulatory questions about how to classify and test it.
Mimi
True, but the non-invasive delivery—just an eye drop—is a huge advantage if it works. Millions of people have dry eye disease, and most current treatments are just lubricants or anti-inflammatory drugs that don't address the root problem.
Mark
So this is genuinely new?
Mimi
Yes. Using photosynthetic machinery to generate antioxidants in human tissue is not something that's been done before. It's a completely different approach to the problem.
Le Pouls
- Dry eye disease traps the cornea in a 'death spiral' — inflammation produces reactive oxygen species that overwhelm the eye's defenses, generating still more damage in an accelerating loop.
- Current treatments address symptoms like dryness or surface inflammation but leave the underlying oxidative destruction untouched, offering millions of sufferers only partial relief.
- NUS researchers broke from convention entirely, extracting photosynthetic machinery from spinach and engineering it into an eye drop that delivers plant-derived structures directly to corneal cells.
- Once inside the eye, these structures allow corneal cells to harvest ambient light and independently produce NADPH — the protective molecule the inflamed eye can no longer make fast enough on its own.
- The treatment requires no surgery and no systemic medication — just a drop — placing a genuinely novel biological mechanism within reach of everyday clinical use, pending the long road of trials ahead.
In laboratories at the National University of Singapore, researchers have looked to the quiet chemistry of spinach leaves to find a new answer to a condition that quietly diminishes the lives of millions. Dry eye disease, long understood as a cycle of inflammation feeding on itself, may now be interrupted not by suppressing the body's responses but by gifting corneal cells a plant-derived capacity to generate their own protection from light. Published in Cell, the work asks whether one of nature's oldest energy solutions might become medicine's newest tool.
At the National University of Singapore, a research team led by Associate Professor David Leong Tai Wei has developed an experimental eye drop that borrows its core mechanism from plant biology. Published in Cell, the treatment uses photosynthetic structures derived from spinach to help corneal cells do something they struggle to do when inflamed: protect themselves.
Dry eye disease is not simply a matter of insufficient tears. At the cellular level, inflammation causes the cornea to generate reactive oxygen species — unstable molecules that damage tissue. A healthy eye counters these with NADPH, a molecule that powers the eye's antioxidant defenses. But when inflammation accelerates, NADPH production cannot keep pace, and the resulting damage drives further inflammation. The researchers describe this as a death spiral: a self-sustaining cycle of destruction with no natural exit.
Rather than targeting inflammation directly or augmenting the eye's existing defenses, the NUS team introduced plant-derived photosynthetic components into corneal cells. These structures allow the cells to capture ambient light and manufacture NADPH independently — a second production pathway that bypasses the one overwhelmed by disease. The mechanism is fundamentally additive, working alongside the eye's own biology rather than overriding it.
What makes the approach notable beyond its novelty is its simplicity. The treatment is delivered as an eye drop, requiring no surgery and carrying no systemic side effects. For a condition that affects millions globally — from screen-fatigued workers to patients with autoimmune disorders — the accessibility of the delivery method matters as much as the science behind it.
The research remains in its experimental stages, and clinical application is still distant. But the underlying insight — that plants have long mastered the management of oxidative stress under light, and that this mastery can be translated into human tissue — points toward a treatment philosophy that is genuinely new: not suppression, not substitution, but biological augmentation drawn from the living world.
At the National University of Singapore, researchers have taken an unlikely path toward treating dry eye disease: they borrowed a trick from spinach. The team, led by Associate Professor David Leong Tai Wei from the Department of Chemical and Biomolecular Engineering, has developed an experimental eye drop treatment that harnesses photosynthetic machinery—the same biological apparatus plants use to convert sunlight into energy—and delivers it directly to the cornea. The work, published in Cell, describes an approach that is simple, effective, and entirely non-invasive.
Dry eye disease is a condition rooted in a destructive cycle at the cellular level. When the cornea becomes inflamed, it generates reactive oxygen species, chemically unstable molecules that damage cells and tissue. In a healthy eye, a molecule called NADPH acts as a cellular shield, powering antioxidant systems that neutralize these aggressive molecules before they can cause harm. But in an inflamed eye, the production of reactive oxygen species accelerates beyond what the cornea's natural defenses can handle. More damage begets more inflammation, which begets more reactive oxygen species—what the researchers call a death spiral, a self-perpetuating cascade of cellular destruction.
The NUS team approached this problem from an entirely different angle. Rather than trying to suppress inflammation or boost the eye's existing antioxidant machinery, they introduced functional photosynthetic structures derived from plants directly into corneal cells. These plant-derived components enable the eye cells to harvest ambient light and manufacture NADPH on their own, independent of the cells' normal NADPH-production pathways. In effect, they gave corneal cells a second way to generate the protective molecule they desperately need when inflammation strikes.
The treatment arrives as an eye drop, making it accessible and easy to administer. The light-activated technology works at the cellular level, meaning patients would not need to undergo surgery or endure systemic side effects. The simplicity of the delivery mechanism—a drop applied to the eye—combined with the fundamental novelty of the approach, suggests a pathway that could reach patients who currently have limited options for managing this chronic condition.
Dry eye disease affects millions of people worldwide, from those who spend long hours at screens to patients with autoimmune conditions that damage tear-producing glands. Current treatments typically focus on lubricating the eye or suppressing inflammation, but they do not address the underlying oxidative stress that perpetuates the damage. By introducing a biological system that can generate its own antioxidant support in response to light, the NUS researchers have proposed something genuinely different: a treatment that works with the eye's own cellular machinery rather than against it.
The work remains experimental, and the path from laboratory findings to clinical use is long. But the core insight—that plants have already solved the problem of managing oxidative stress under light, and that this solution can be adapted for human tissue—opens a new direction for how dry eye disease might be treated. For the millions of people whose eyes fail to produce adequate tears or whose corneas are ravaged by inflammation, this represents a fundamentally different kind of hope.
Citations marquantes
In inflamed eyes, reactive oxygen species can overwhelm the cornea's natural defenses, resulting in further ROS generation and creating a 'death spiral'— Associate Professor David Leong Tai Wei, National University of Singapore
Envie de l'histoire complète ?
Lire l'original sur NZ Optics ↗
Education